Roivant Sciences slides as investors digest LISRAYA launch outlook after FDA approval

Roivant Sciences (ROIV) is down 7.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied less to a negative regulatory surprise and more to a classic sell-the-news reaction after Roivant won FDA approval for LISRAYA in dermatomyositis. Management also framed the launch as likely to be “slow and steady,” which may have tempered expectations for a fast commercial ramp even as the approval itself was a major milestone.

Details:

Roivant announced on August 27 that the FDA approved LISRAYA, making it available immediately in the U.S. for adults with dermatomyositis.

On the August 28 launch call, management set a wholesale acquisition cost of $35,000 for a 30-day supply and described annual net value per treated patient as only roughly in the low-to-mid $300,000 range after adjustments.

Executives repeatedly emphasized that orphan-disease launches take time and said they expect adoption to build gradually rather than surge right away.

This could be because traders were positioned for the approval and then locked in gains once the market shifted from regulatory upside to questions about reimbursement, physician adoption, and early sales visibility.

Sources:

Roivant Sciences, SEC, Reuters

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ROIV Insider Trading Activity

$ROIV insiders have traded $ROIV stock on the open market 38 times in the past 6 months. Of those trades, 0 have been purchases and 38 have been sales.

Here’s a breakdown of recent trading of $ROIV stock by insiders over the last 6 months:

MAYUKH SUKHATME (President & CIO) has made 0 purchases and 9 sales selling 2,000,000 shares for an estimated $70,626,215.
KEITH S MANCHESTER has made 0 purchases and 6 sales selling 1,638,163 shares for an estimated $56,444,075.
FINANCIAL LP QVT has made 0 purchases and 5 sales selling 1,438,163 shares for an estimated $49,354,075.
DANIEL ALLEN GOLD has made 0 purchases and 5 sales selling 1,438,163 shares for an estimated $49,354,075.
ERIC VENKER (President & Immunovant CEO) has made 0 purchases and 6 sales selling 1,000,000 shares for an estimated $31,241,267.
MATTHEW GLINE (CEO) sold 289,774 shares for an estimated $8,449,809
MEGHAN FITZGERALD has made 0 purchases and 2 sales selling 80,000 shares for an estimated $2,270,500.
MELISSA B, EPPERLY has made 0 purchases and 3 sales selling 59,611 shares for an estimated $1,810,825.
JENNIFER HUMES (Chief Accounting Officer) sold 13,538 shares for an estimated $384,073

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ROIV Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ROIV Hedge Fund Activity

We have seen 298 institutional investors add shares of $ROIV stock to their portfolio, and 199 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FARALLON CAPITAL MANAGEMENT LLC added 9,638,000 shares (+26048.6%) to their portfolio in Q1 2026, for an estimated $266,972,600
MORGAN STANLEY removed 9,235,420 shares (-17.8%) from their portfolio in Q2 2026, for an estimated $326,841,513
GOLDMAN SACHS GROUP INC added 7,444,867 shares (+67.0%) to their portfolio in Q2 2026, for an estimated $263,473,843
UBS GROUP AG removed 5,152,831 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $182,358,689
BLACKROCK, INC. added 3,981,831 shares (+9.0%) to their portfolio in Q2 2026, for an estimated $140,916,999
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,715,594 shares (+inf%) to their portfolio in Q2 2026, for an estimated $131,494,871
POINT72 ASSET MANAGEMENT, L.P. added 3,582,578 shares (+402.1%) to their portfolio in Q2 2026, for an estimated $126,787,435

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ROIV Price Targets

Multiple analysts have issued price targets for $ROIV recently. We have seen 5 analysts offer price targets for $ROIV in the last 6 months, with a median target of $40.0.

Here are some recent targets:

Yatin Suneja from Guggenheim set a target price of $36.0 on 05/26/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $34.0 on 05/21/2026
Yaron Werber from TD Cowen set a target price of $41.0 on 05/21/2026
Samantha Semenkow from Citigroup set a target price of $42.0 on 05/21/2026
Yasmeen Rahimi from Piper Sandler set a target price of $40.0 on 04/16/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.